Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4515100 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| LY4515100 | EXPERIMENTAL | Administered Orally |
| Placebo | PLACEBO_COMPARATOR | Administered Orally |
| Name | Type | Description |
|---|---|---|
| LY4515100 | DRUG | Administered Orally |
| Placebo | DRUG | Administered Orally |
Inclusion Criteria: * Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²) inclusive. * Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray. Exclusion...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | N/A | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | - | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | - | Flozin |
LY4515100 is an investigational small molecule being developed for the treatment of acute pain. It is currently being studied in a Phase 2 clinical trial for pain following third molar removal surgery. The drug is being evaluated for its ability to manage acute pain in this setting.
LY4515100 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for acute pain.
LY4515100 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating acute pain following third molar removal.
LY4515100 is being studied in a Phase 2 clinical trial with the identifier NCT07511816. This randomized, double-blind, placebo-controlled study is evaluating the drug in 212 participants with pain following third molar removal. The trial is currently recruiting participants in the United States.
LY4515100 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The drug is being studied in a clinical trial for acute pain following third molar removal, but it has not yet received regulatory approval for any use.